Table I.
Factor | Value |
---|---|
Age, years | |
Mean ± S.D. | 70.5±9.82 |
≤70 | 15(50) |
>70 | 15(50) |
Sex | |
Male | 13(43) |
Female | 17(57) |
Fracture site | |
Femoral neck | 5(17) |
Femoral diaphysis | 5(17) |
Intertrochanteric | 6(20) |
Subtrochanteric | 10(33) |
Bilateral intertrochanteric | 1(3) |
Proximal tibia | 2(7) |
Distal femur | 1(3) |
Type of cancer | |
Lung | 9(30) |
Breast | 7(23) |
Kidney | 3(10) |
Multiple myeloma | 4(13) |
Liver | 2(7) |
Gastric | 2(7) |
Unknown | 1(3) |
Esophageal | 1(3) |
Uterine | 1(3) |
N. metastases | |
≤3 | 4(13) |
>3 | 26(87) |
ECOG-PS (mean) | 2 |
<2 | 14(47) |
2-3 | 14(47) |
>3 | 2(7) |
Adjuvant therapy | |
Radiotherapy | 2(7) |
Chemotherapy | 15(50) |
Chemotherapy and radiotherapy | 10(33) |
None | 3(10) |
Treatment modality | |
Intramedullary nail | 16(53) |
Endoprosthesis | 1(3) |
Fixation with plate | 1(3) |
Bipolar head arthroplasty | 3(10) |
Fixation with CHS | 3(10) |
Bilateral intermedullary nail | 2(7) |
Conservative | 2(7) |
Artificial bone stem | 1(3) |
Rt. bipolar head arthroplasty, Lt. fixation with CHS | 1(3) |
Operating time, min | |
Total | 92.0±38.7 |
Impending fractures | 83.1±21.9a |
Pathological fractures | 113.8±44.3 |
0-100 | 17 |
>100 | 11 |
Blood loss, ml | |
Total | 50.0 (20-447) |
Impending fractures | 46.4 (20-435) |
Pathological fractures | 132.6 (20-447) |
0-60 | 15 |
>60 | 13 |
MSTS score | |
Intramedullary nailing | 19.9±8.8 |
Other surgical procedures | 22.0±10.9 |
0-10 | 8(27) |
11-20 | 7(23) |
21-30 | 15(50) |
Outcome | |
AWD | 19(63) |
DOD | 11(37) |
Follow-up period, months | |
Mean | 6.5 |
Range | 1-150 |
Values are expressed as n (%), the mean ± S.D. or median (range).
aP<0.05 vs. pathological fractures. Rt, right side; Lt, left side; S.D., standard deviation; ECOG-PS, Eastern Cooperative Oncology Group score for performance status; CHS, compression hip screw; MSTS, Musculoskeletal Tumor Society; CDF, continuous disease-free; AWD, alive with disease; DOD, dead of disease.